Curis Lifesciences Ltd Company Summary

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name and style of M/s Loreto Pharmaceutacals, pursuant to a Deed of Partnership dated 2 June, 2010. Thereafter M/s Loreto Pharmaceutacals was converted from Partnership Firm to a Private Limited Company as Curis Lifesciences Private Limited and received a Certificate of Incorporation dated on March 23rd, 2016 issued by Registrar of Companies, Ahmedabad. Subsequently, Company was converted into a Public Limited Company and the name of the Company was changed from Curis Lifesciences Private Limited to Curis Lifesciences Limited vide certified incorporated upon the conversion dated August 9, 2024, issued by the Central Processing Centre, Manesar.Companys business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic.

The business is majorly on product to product basis with different marketers. Company has commenced manufacturing facility in year 2017, hence, it has experience of more than 7 years in the current line of business of the Company. The manufacturing facility of the Company is installed with capacity to manufacture 138 Crore tables / year, 15.75 Crore Capsules / year, 1,080 Kilolitre Oral Liquid/ year, 270 Tons external preparation / year and 45 Tons sterile ophthalmic ointment / year.

It deal in Pharmaceutical products like Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments etc.The Companys past and present clientele includes renowned pharma marketers and manufactures namely Arova Pharma, Express Pharmaceuticals Private Limited, Angle Biogenics Private Limited, Centurion Healthcare Private Limited, Costcon Healthcare LLP, J.B. Chemical & Pharmaceuticals Limited, Venus international, Makers Laboratories Limited and Torikaa Pharmaceuticals Limited etc. pharmaceutical manufacturing facility are situated at Sanand GIDC-II in Ahmedabad district of Gujarat, which offers easy and convenient accessibility.Company is planning an Initial Public Issue of upto 22,50,000 Equity Shares of face value of Rs 10 each through fresh issue.